New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus

Anais Brasileiros de Dermatologia

Victor Pavan Pasin¹  Amanda Regio Pereira¹  Kalline Andrade De Carvalho¹  João Marcos Góes De Paiva¹  Milvia Maria Simões E Silva Enokihara¹  Adriana Maria Porro¹ 

关键词: Drug eruptions;    Immunosuppressive agents;    Ulcer;   

DOI  :  10.1590/abd1806-4841.20153672

来源: SciELO

【 摘 要 】

Abstract Everolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who developed disfiguring oral and perianal ulcers secondary to everolimus's toxicity. This is probably the first report of perianal involvement. Dermatologists need to be aware of the potential mucocutaneous adverse effects related to these new drugs that are becoming evermore common in our clinical practice.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License